Skip to main content

Table 3 Cardiac function measured with echocardiography

From: Green tea extract catechin improves cardiac function in pediatric cardiomyopathy patients with diastolic dysfunction

Parameter

Study inclusion (n = 12)

6 months after study start (n = 10)

P-value*

12 months after study start (n = 9)

P-value**

HR (bpm)

93 ± 26

91 ± 18

ns

86 ± 19

ns

Systolic BP (mmHg)

96 ± 18

104 ± 12

ns

97 ± 16

ns

Diastolic BP (mmHg)

59 ± 12

60 ± 5

ns

57 ± 15

ns

LVESD (mm)

20 ± 8

21 ± 7

ns

21 ± 8

ns

LVEDD (mm)

31 ± 9

34 ± 8

ns

32 ± 9

ns

LVESV (ml)

16 ± 14

18 ± 12

ns

19 ± 17

ns

LVEDV (ml)

40 ± 28

53 ± 28

0.028

48 ± 33

0.011

SV (ml)

25 ± 16

32 ± 17

0.022

30 ± 17

0.021

EF (%)

68 ± 14

69 ± 14

ns

67 ± 10

ns

FS (%)

38 ± 13

39 ± 11

ns

37 ± 7

ns

E/A

1.3 ± 0.7

1.3 ± 0.7

ns

1.7 ± 0.6

0.018

IVRT (ms)

115 ± 46

100 ± 42

0.047

94 ± 30

0.033

RVSP (mmHg)

29 ± 8

30 ± 6

ns

30 ± 5

ns

  1. Notes: A mitral Doppler A peak velocity, BP blood pressure, E mitral Doppler E peak velocity, EF ejection fraction, FS fractional shortening of LV, HR heart rate, IVRT isovolumetric relaxation time, LVEDD left ventricle end diastolic dimension, LVEDV left ventricle end diastolic volume, LVESD, left ventricle end systolic dimension, LVESV left ventricle end systolic volume, ns nonsignificance, RVSP right ventricle systolic pressure, SV stroke volume. Continuous data are expressed as mean ± SD. *6 months after study start vs study inclusion; **12 months after study start vs study inclusion